Press Releases

September, 12 2018

The Foundation for the National Institutes of Health (FNIH) will honor 22-year-old Andrew Lee, President and CEO of Driven to Cure, Inc., with the 2018 Charles A. Sanders, M.D., Partnership Award. The award honors persons and/or organizations that have made significant contributions to the FNIH’s work to build, implement and nurture public-private partnerships in support of the mission of the National Institutes of Health (NIH).

 

July 31, 2018

The Foundation for the National Institutes of Health (FNIH) has selected three finalists of the inaugural Trailblazer Prize for Clinician-Scientists (Trailblazer Prize): Daniel Bauer, M.D., Ph.D., Harvard Medical School, Jaehyuk Choi, M.D., Ph.D., Feinberg School of Medicine, Northwestern University and Michael Fox, M.D., Ph.D., Beth Israel Deaconess Medical Center, Harvard Medical School.

July 30, 2018

The Foundation for the National Institutes of Health (FNIH) and the Cancer Research Institute (CRI) announced today that FNIH has selected CRI to be its source of landscape intelligence in immuno-oncology, also called cancer immunotherapy. 

July 24, 2018

The Board of Directors of the Foundation for the National Institutes of Health (FNIH) has elected world-renowned scientific leader Marijn Dekkers, Ph.D., Chairman of Unilever, as its newest member. Dr. Dekkers’ appointment took effect on May 17, 2018.

 
April 3, 2018

Prize bestowed to Dr. Zhijian “James” Chen for discovery of the cGAS enzyme and its DNA-sensing pathway and their impact on immune defense and autoimmune disease.

February 21, 2018

Datasets characterizing individual cells in rheumatoid arthritis and systemic lupus erythematosus disease tissue from the Accelerating Medicines Partnership for Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Phase I study are now available to the research community. Scientists from across the biomedical research community can access the AMP RA/SLE datasets to explore important research questions about these autoimmune conditions.

January 30, 2018

The National Institutes of Health is teaming with government, biopharmaceutical, life science and non-profit organizations to overcome obstacles and increase success for advancing promising treatments for Parkinson’s disease (PD). Part of the NIH Accelerating Medicines Partnership (AMP), AMP PD will focus on identifying and validating promising markers of disease called biomarkers that may be useful in tracking the progression of PD and could serve as biological targets for the development of new drugs.

January 23, 2018

The Foundation for the National Institutes of Health (FNIH) is pleased to open nominations for the inaugural Trailblazer Prize for Clinician-Scientists (Trailblazer Prize). This annual prize and $10,000 honorarium presented by the FNIH recognizes the outstanding contributions of early career clinician-scientists in the United States whose work has the potential to or has led to innovations in patient care. To nominate a colleague for this prize and learn about eligibility criteria, visit fnih.org/TrailblazerPrize. Nominations will be accepted through Friday, March 30 at 1:00 p.m. ET.

November 20, 2017

The Foundation for the National Institutes of Health (FNIH) is proud to announce that it received the Gold Stevie Award for Organization of the Year in the government/nonprofit category of the Women in Business Awards. The FNIH’s President and Executive Director, Maria C. Freire, Ph.D., also received a Gold Stevie Award for Woman of the Year in the government/non-profit category. 

October 12, 2017

The National Institutes of Health and 11 leading biopharmaceutical companies today launched the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot. PACT will initially focus on efforts to identify, develop and validate robust biomarkers — standardized biological markers of disease and treatment response — to advance new immunotherapy treatments that harness the immune system to attack cancer. The partnership will be managed by the Foundation for the National Institutes of Health (FNIH), with the Food and Drug Administration serving in an advisory role.